KRAS and non-small cell lung carcinoma: KRAS mutations were found to be predictive of platinum-based chemotherapy resistance in non-small cell lung cancer (NSCLC) by Skoulidis et al using logistic regression, with an odds ratio of 2.1 (P < 0.001).